Esophageal patients have had little option other than chemotherapy for a long time. Could immunotherapies change that? First Keytruda was approved to treat PD-L1 positive advanced squamous cell esophageal cancer and recently Opdivo (nivolumab) evidenced therapeutic effect, regardless of therapeutic expression, in the Phase III ATTRACTION-3 trial gaining attention along the way.
Professor Cho Byoung-chul with the Medical Oncology Division at Severance Hospital (Yonsei University Health System) presented the ATTRACTION-3 study results at the Annual European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
As reported in The Lancet Oncology, trial was a multi-center, randomized, open-label, Phase III trial at 90 hospitals and cancer centers in Denmark, Germany, Italy, Japan, South Korea, Taiwan, the UK and the USA.
The team found that nivolumab (Opdivo) was associated with a significant improvement in overall survival and a favorable safety profile compared with chemotherapy in previously treated patients with advanced esophageal squamous cell carcinoma and might actually represent a new standard second-line treatment option for esophagus cancer patients.
Clinical Investigator Interview
Korean Biomedical Review published an interview with Professor Cho Byoung-chul with the Medical Oncology Division at Severance Hospital presented the ATTRACTION-3 study results at the Annual European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. He met with Cho to learn the stud results in detail and the clinical implications of Opdivo in the advanced squamous cell esophageal cancer treatment.
Call to Action: Follow the link to read the interesting interview. If you or a loved one has been diagnosed with esophagus cancer, there may be new options on the horizon.